Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Angiosarcoma
25%
Biological Marker
25%
CD8 Antigen
11%
Cell Adhesion Molecule 1
25%
Cell Antigen
25%
Cell Line
25%
Cervical Lymph Node Metastasis
25%
Chemoradiotherapy
25%
Cutaneous T Cell Lymphoma
25%
Cytotoxic T-Cell
25%
Disease
12%
Epstein Barr Virus
75%
Hydroa Vacciniforme
100%
Hypersensitivity
47%
Interferon
16%
Interleukin 2
11%
Large Granular Lymphocyte
25%
Large-Cell Lymphoma
25%
Lipopolysaccharide
25%
Lymphoproliferative Disease
52%
Maintenance Chemotherapy
25%
Mosquito Bite
47%
Mycosis fungoides
8%
Natural Killer Cell
28%
Necrolytic Migratory Erythema
12%
Nivolumab
8%
Nodular Melanoma
25%
Overall Survival
9%
Pellagra
12%
Polyarteritis nodosa
25%
Prognostic Factor
34%
Programmed Death 1 Ligand 1
25%
Programmed Death 1 Receptor
25%
Progression Free Survival
12%
Pseudolymphoma
25%
Radiation Therapy
25%
Retrospective Cohort Study
25%
Scalp
25%
Scoring System
25%
Shock (Circulatory)
10%
Skin Biopsy
25%
Skin Infiltrate
10%
Staphylococcus Enterotoxin
25%
Survival Rate
25%
Symptom
13%
T Cell
65%
T Lymphocyte Receptor
14%
Tattoo
25%
Toxic Shock Syndrome
25%
Tumor Necrosis Factor
16%
Keyphrases
Adult T-cell Leukemia
30%
Adult T-cell Lymphoma
25%
Antibody Efficacy
25%
Antisynthetase Syndrome
25%
Bexarotene
25%
BZLF1
14%
Cell Adhesion Molecule 1 (CADM1)
25%
Cervical Lymph Node Metastasis
25%
Chronic Limb-threatening Ischemia
25%
Concurrent Chemoradiation
25%
Cutaneous Lesions
25%
Cutaneous T-cell Lymphoma
25%
Epithelial Neoplasm
8%
Epstein-Barr Virus
50%
Epstein-Barr Virus DNA Load
9%
Epstein-Barr Virus Reactivation
25%
FAS1
16%
FAS2
8%
Gastrointestinal Involvement
25%
Hydroa Vacciniforme
50%
Hypersensitivity to Mosquito Bites
39%
Institutional Experience
25%
Intravascular Large B-cell Lymphoma (IVLBCL)
25%
Laboratory Markers
25%
Leukemia
25%
Lymphoproliferative Disorders
15%
Maintenance Chemotherapy
25%
Molluscum Contagiosum
25%
Mycosis Fungoides
8%
Natural Killer
8%
Necrolysis
12%
Necrolytic Migratory Erythema
12%
Overall Survival Progression-free Survival
9%
Papiliotrema
25%
Patient Prognosis
25%
Pellagra
12%
Phase II Study
25%
Pseudolymphoma
25%
Radiation Therapy
25%
Random Skin Biopsy
25%
Retrospective Cohort Study
25%
Scalp Angiosarcoma
25%
Scoring System
25%
Skin Lesions
10%
Splice Variant
25%
T Cells
19%
T-cell Large Granular Lymphocytes
25%
T-cell Lymphoproliferative Disorder
25%
Tattoo Ink
16%
Taxanes
25%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
9%
Anaplastic Large Cell Lymphoma
8%
Antisynthetase Syndrome
25%
Atopic Dermatitis
32%
Bexarotene
25%
Biological Marker
27%
Brentuximab Vedotin
25%
CD8 Antigen
25%
Chymotrypsin
9%
Clinical Trial
27%
Cutaneous T Cell Lymphoma
25%
Cytokine
24%
Disseminated Intravascular Clotting
5%
Erythema
5%
Fasciitis
5%
Interferon
16%
Interleukin 2
8%
Interleukin 6
5%
Kallikrein
6%
Klebsiella pneumoniae
5%
Lipopolysaccharide
25%
Malignant Neoplasm
5%
Melanoma
25%
Methicillin Resistant Staphylococcus Aureus Infection
5%
Mouse
5%
Mycosis fungoides
8%
Neoplasm
11%
Nivolumab
8%
Normal Human
10%
Peptidase
6%
Programmed Death 1 Ligand 1
25%
Programmed Death 1 Receptor
25%
Proteinase
39%
Psoriasis
7%
Septic Shock
5%
Serine Peptidase Inhibitor Kazal Type 5
21%
Serine Proteinase
50%
Serine Proteinase Inhibitor
10%
Skin Defect
11%
Staphylococcus Aureus
5%
Staphylococcus Enterotoxin
25%
Superantigen
5%
Symptom
5%
T Cell Leukemia
25%
T Lymphocyte Receptor
7%
Tolerability
6%
Toxic Shock Syndrome
25%
Toxic Shock Syndrome Toxin 1
5%
Tumor Necrosis Factor
41%
Ulcer
5%